Moreover, we showed that SMYD3 activity is crucial for cancer cell DDR response to chemotherapy and mediates the repair of CHT-induced DSBs by methylating ATM and therefore activating the ATM-CHK2-p53 cascade. This evidence concerns the gene TP53 and cancer.